This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harlan, L. C. Articles by Ballard-Barbash, R. Search for Related Content PubMed PubMed Citation Articles by Harlan, L. C. Articles by Ballard-Barbash, R.

Community-Based Use of Chemotherapy and Hormonal Therapy for Early-Stage Breast Cancer: 1987-2000

From the Applied Research Program; Surveillance Research Program; and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda; Information Management Systems, Silver Spring, MD

Address reprint requests to Linda C. Harlan, National Cancer Institute, 6130 Executive Blvd, MSC 7344, Bethesda, MD 20892-7344; e-mail: lh50w{at}nih.gov

PURPOSE: We describe trends in the use of chemotherapy and hormonal therapy by nodal and estrogen receptor (ER) status in women with early-stage breast cancer.

METHODS: Cases were randomly sampled from the population-based Surveillance, Epidemiology and End Results (SEER) program and physician verified treatment was examined. A total of 9,481 women, aged 20 years and older, diagnosed with early-stage breast cancer in 1987 to 1991, 1995, and 2000 were included in the study.

RESULTS: The use of chemotherapy plus tamoxifen increased between 1995 and 2000 for women with node-negative, ER-positive breast cancer 1 cm (8% to 21%). Nearly 23% of women with node-negative and ER-positive tumors 1 cm received no adjuvant therapy. The use of chemotherapy alone increased to nearly 60% in women with node-negative, ER-negative tumors 1 cm (48% to 59%). However, in 2000, 16% of women with node-positive and ER-negative tumors received no adjuvant therapy and an additional 6% received tamoxifen alone. The influence of age can clearly be seen. Chemotherapy is given much less often in women 70 years or older.

CONCLUSION: The results from SEER areas across the United States suggest that physicians quickly responded to publications and guidelines regarding breast cancer therapy. The lack of definitive findings from clinical trials on the use of adjuvant therapy in women 70 years and older may explain the lower use in this group of women.

Supported by funding from the following: contract numbers: N01-PC-35133, N01-PC-35135, N01-PC-35136, N01-PC-35137, N01-PC-35138, N01-PC-35139, N01-PC-35141, N01-PC-35142, N01-PC-35143, N01-PC-35145.

Results reported here have not been published elsewhere. The manuscript makes use of data published: Harlan LC, Abrams J, Warren J, Clegg L, Stevens J, Ballard-Barbash R: Adjuvant therapy for breast cancer: Practice patterns of community physicians. J Clin Oncol 20:1809-1817, 2000.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				J. L. Warren, A. B. Mariotto, A. Meekins, M. Topor, and M. L. Brown Current and Future Utilization of Services From Medical Oncologists J. Clin. Oncol., July 1, 2008; 26(19): 3242 - 3247. [Abstract] [Full Text] [PDF]

				K. A. Vanderveen, D. A. Paterniti, R. L. Kravitz, and R. J. Bold Diffusion of Surgical Techniques in Early Stage Breast Cancer: Variables Related to Adoption and Implementation of Sentinel Lymph Node Biopsy Ann. Surg. Oncol., May 1, 2007; 14(5): 1662 - 1669. [Abstract] [Full Text] [PDF]